

# MARYLAND PHARMACY PROGRAM

**Medicaid - Pharmacy Assistance - Pharmacy Discount** 

No. 5B Tuesday, January 6, 2004

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Department of Health and Mental Hygiene's (DHMH) *Maryland Pharmacy Program* (MPP) has developed the **Maryland Pharmacy Program Advisory**. To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations. It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via DHMH, please contact the MPP representative at 410-767-5395.

# PREFERRED DRUG LIST (PDL): LATEST CUMULATIVE UPDATE OF THERAPEUTIC CLASSES (TO BE IMPLEMENTED BY FEBRUARY 2004)

The Department of Health and Mental Hygiene's Pharmacy and Therapeutics Committee has completed development of the first full set of classes for the Preferred Drug List (PDL). This Advisory #5B and the attached PDL <u>supersede</u> any former PDL versions. All Maryland Medicaid rules and edits remain in effect.

Please note: The PDL will not apply to those patients currently under treatment using medications from the following two categories. The categories are:

- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Stimulants and Related Agents

For <u>new</u> prescriptions for the above categories where the patient has no recent history (90 days) of therapy, the PDL rules will apply.

Full consideration for the recipient continues to be a top priority. The prescriber and pharmacist are encouraged to review the available options for drug therapy within the Preferred Drug List. Recipients having problems obtaining prescribed medications from the pharmacy may call the Maryland Pharmacy Access Hotline at 1-800-492-5231. If you (the pharmacy) have any questions, contact the Department at 410-767-1455.

#### **For Additional Information**

To obtain current and additional information about the Maryland Preferred Drug List, please feel free to visit the following websites:

Department of Health and Mental Hygiene <a href="http://www.dhmh.state.md.us/mma/mpap/prefdruglist.html">http://www.dhmh.state.md.us/mma/mpap/prefdruglist.html</a>

Provider Synergies <a href="http://providersynergies.com">http://providersynergies.com</a>

First Health Services Corporation <a href="http://mdmedicaidrx.fhsc.com">http://mdmedicaidrx.fhsc.com</a>

**December 12, 2003** 

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred.

Only drugs listed within the therapeutic categories are affected by the PDL. Therapeutic categories not listed here are not part of the PDL and will continue to be covered for Maryland Pharmacy Program patients.

#### **ANALGESIC**

## Anti-Migraine Agents, Triptans (Anti-Migraine Preparations) Effective as of January 7, 2004

#### **Preferred**

Amerge Imitrex (oral, nasal & subq)

Maxalt, MLT

#### Requires Prior Authorization

Axert Frova Relpax

Zomig, Nasal, ZMT

# Nonsteroidal Anti-Inflammatories/COX II Inhibitor (NSAIDS, Cyclooxygenase Inhibitor – Type)

Effective as of November 19, 2003

#### Preferred

diclofenac potassium (Cataflam) diclofenac sodium, XL (Voltaren, XR) etodolac, XL (Lodine, XL)

fenoprofen (Nalfon) flurbiprofen (Ansaid) ibuprofen (Motrin)

indomethacin, SR (Indocin, SR) ketoprofen (Orudis, Oruvail)

ketorolac (Toradol)

meclofenamate (Meclomen)

nabumetone (Relafen) naproxen (Naprosyn)

naproxen sodium, DS (Anaprox, DS)

oxaprozin (Daypro) piroxicam (Feldene) sulindac (Clinoril)

tolmetin, DS (Tolectin, DS)

#### **Requires Prior Authorization**

Arthrotec Bextra Celebrex Mobic Ponstel Vioxx

#### Narcotic Analgesics

#### Effective as of January 7, 2004

#### Preferred

acetaminophen w/codeine (Oral) aspirin w/codeine (Oral)

Avinza (Oral)

butalbital/apap/caffeine (Oral) butalbital/caff/apap/codeine (Oral)

codeine phosphate/sulfate (oral) Duragesic (Transderm)

hydrocodone bit-ibuprofen (Oral)

hydrocodone w/acetaminophen

(Oral)

hydromorphone HCI (Oral)

Kadian (Oral)

meperidine HCI (Oral)

morphine sulfate/IR (Oral

oxycodone HCI (Oral)

oxycodone w/acetaminophen(Oral)

oxycodone w/aspirin (Oral)

Panlor DC/SS (Oral)

pentazocine-naloxone (Oral)

propoxyphene HCI/compound

(Oral)

propoxyphene HCI w/apap (Oral)

propoxyphene napsylate w/apap

(Oral)

roxicodone (Oral)

tramadol HCl (oral)

Ultracet (Oral)

#### Requires Prior Authorization

Darvon-N (oral)
Percocet (Oral)
Oxycontin (Oral)
Synalgos-DC (Oral)
Actig (Buccal)

#### **December 12, 2003**

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred.

#### **ANTI-INFECTIVES**

## Antifungals, Oral (Antifungal Agents, Antifungal Antibiotics) Effective as of January 21, 2004

#### Preferred

griseofulvin (Fulvicin) ketoconazole (Nizoral) nystatin Diflucan Grifulvin V

Lamisil

Oxistat

Valcyte

#### Requires Prior Authorization

Ancobon Mycelex Troche Mycostatin Pastilles Sporanox Vfend

## Antifungals, Topical (Topical Antifungals) Effective as of January 21, 2004

#### Preferred

clotrimazole (Lotrimin)
clotrimazole/betamethasone (Lotrisone)
econazole (Spectazole)
ketoconazole (Nizoral)
nystatin (Mycostatin)
nystatin/triamcinolone (Mycolog II)
Exelderm
Naftin
Nizoral Shampoo

#### Requires Prior Authorization

Loprox Loprox Shampoo Mentax Penlac

# Antivirals (Antivirals, General) Effective as of December 17, 2003

#### Preferred

acyclovir (Zovirax)
amantadine (Symmetrel)
rimantadine (Flumadine)
Cytovene
Famvir
Tamiflu

#### Requires Prior Authorization

Relenza Valtrex

# Cephalosporin and Related Agents (Cephalosporins, Second and Third Generation, Penicillins) Effective as of January 21, 2004

Preferred
amoxicillin/clavulanate (Augmentin)
cefaclor (Ceclor, CD)
cefadroxil (Duricef)
cefuroxime (Ceftin)
cephalexin (Keflex)
Augmentin ES-600, XR
Omnicef
Spectracef

#### Fluoroquinolones (Quinolones) Effective as of December 17, 2003

<u>Preferred</u>	Requires Prior Authorization
ofloxacin (Floxin)	ciprofloxacin
Avelox, IV	Floxin IV
Cipro, XR, IV	Levaquin, IV
	Maxaquin
	Noroxin
	Teauin, IV

#### Macrolides - Effective as of December 17, 2003

· · · · · · · · · · · · · · · · · · ·	
<u>Preferred</u>	Requires Prior Authorization
erythromycin Biaxin, XL Dynabac Zithromax	none

**December 12, 2003** 

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred.

#### **CARDIOVASCULAR**

#### ACE Inhibitor/Calcium Channel Blocker Combination

Effective as of November 5, 2003

Preferred

Requires Prior Authorization

Lexxel Lotrel Tarka

none

#### **ACE Inhibitors (Hypotensives, ACE Inhibitors)**

Effective as of December 3, 2003

**Preferred** 

captopril, HCTZ (Capoten,

Capozide) enalapril, HCTZ (Vasotec,

Vaseretic)

lisinopril, HCTZ (Prinivil,

Zestril,

Prinzide, Zestoretic) moexipril (Univasc)

Aceon

Monopril, HCT

Uniretic

Requires Prior Authorization

Accupril, Accuretic Altace

Lotensin, HCT

Mavik

#### Angiotensin Receptor Blockers (Hypotensives, Angiotensin Receptor Antagonist)

Effective as of November 19, 2003

Preferred

Requires Prior Authorization

Avapro, Avalide Benicar, HCT

Cozaar, Hyzaar Diovan, HCT

Micardis, HCT

Atacand, HCT Teveten, HCT

#### Beta Blockers (Alpha/Beta-Adrenergic Blocking Agents, **Beta-Adrenergic Blocking Agents)**

Cartrol

Levatol

Innopran XL

Preferred

acebutolol (Sectral) atenolol (Tenormin)

betaxolol (Kerlone)

bisoprolol (Zebeta)

labetalol (Normodyne,

Trandate)

metoprolol (Lopressor)

nadolol (Corgard)

pindolol (Visken)

propranolol (Inderal)

sotalol, AF (Betapace, AF) timolol (Blocadren)

Corea

Toprol XL

Effective as of November 5, 2003

Requires Prior Authorization

#### Calcium Channel Blocking Agents Effective as of December 3, 2003

Preferred

diltiazem (Cardizem)

diltiazem SR, ER (Cardizem SR, CD. Dilacor XR. Tiazac)

nicardipine (Cardene)

nifedipine, SR (Adalat, CC,

Procardia, XL)

verapamil (Calan)

verapamil ER, SR (Calan SR,

Verelan)

Dynacirc, CR

Norvasc

Plendil Sular

Cardizem LA Covera-HS Nimotop Vascor

Verelan PM

Cardene SR

Requires Prior Authorization

**December 12, 2003** 

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred.

#### **Lipotropics, Other (Lipotropics, Bile Salt Sequestrants)** Effective as of November 5, 2003

Requires Prior Authorization Preferred cholestyramine (Questran, Light) aemfibrozil (Lopid) niacin (Niacor) Advicor Colestid Niaspan Tricor

Lofibra Welchol Zetia

#### **Lipotropics, Statins (Lipotropics)**

Effective as of December 3, 2003

Preferred Requires Prior Authorization lovastatin (Mevacor) Crestor Pravigard PAC Altocor Lescol, XL Lipitor Pravachol Zocor

#### **ENDOCRINE**

**Bone Resorption Suppression and Related Agents (Bone** Resorption Inhibitors, Bone Formation Stim. Agents -**Parathyroid Hormone**)

Effective as of January 7, 2004

Preferred Requires Prior Authorization

Actonel Didronel Fosamax Evista Miacalcin Forteo

#### **Estrogen Agents, Combination (Estrogenic Agents)** Effective as of January 7, 2004

Preferred Requires Prior Authorization Activella **FemHRT** 

Combinatch Prefest Premphase Prempro

#### Estrogen Agents, Oral and Transdermal (Estrogenic Agents) Effective as of January 7, 2004

Preferred Requires Prior Authorization estradiol (Estrace) Cenestin estradiol transdermal patches Menest (Estraderm) estropipate (Ogen, Ortho-Est) Premarin

#### Hypoglycemics, Insulin Effective as of January 21, 2004

#### Preferred Requires Prior Authorization Lantus Humulin Novolin Humalog Novoloa **Humalog Mix** Novolog Mix

#### Hypoglycemics, TZDs (Hypoglycemics, Insulin-Response Enhancers)

Effective as of December 17, 2003

Preferred Requires Prior Authorization Avandia Actos

**December 12, 2003** 

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred.

**GASTROINTESTINAL** 

**Proton Pump Inhibitors (Gastric Acid Secretion Reducers)** 

Effective as of November 5, 2003

Preferred Requires Prior Authorization

Aciphex omeprazole Prevacid Nexium

Prilosec Protonix <u>Preferred</u>

Requires Prior Authorization

Accolate

Nasal Corticosteroids (Nasal Anti-Inflammatory Steroids)

Effective as of November 19, 2003

Preferred

flunisolide (Nasalide)

Flonase Nasonex

Singulair

Requires Prior Authorization

Beconase AQ Nasacort AQ Nasarel

Rhinocort Aqua

**RESPIRATORY** 

Inhaled Corticosteroids (Beta-Adrenergics and Glucocorticoids Combination, Glucocorticoids)

Effective as of November 5, 2003

Preferred

Advair Diskus Aerobid, Aerobid M

Azmacort

Flovent, Rotadisk

Qvar

Pulmicort Respules (Ages 1-8)

Requires Prior Authorization

Pulmicort Respules (Over Age 8, Under Age 1)

Pulmicort Turbuhaler

doxa

**Leukotriene Receptor Antagonists** 

Effective as of November 5, 2003

**UROLOGIC** 

Benign Prostatic Hyperplasia (Alpha-Adrenergic Blocking Agents)

Effective as of November 5, 2003

Preferred

Requires Prior Authorization

doxazosin (Cardura) terazosin (Hytrin)

Avodart Flomax Proscar none

**December 12, 2003** 

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred.

### **Instructions for the Pharmacist**

When the pharmacist submits an on line-prescription for a non-preferred drug product whose class is on the preferred drug list, a message will appear "NON-PREF'D (PA req'd) MD call 1-800-932-3918." The pharmacist should:

- Refer to the PDL reference list
- Notify the customer that the drug prescribed is not a preferred drug
- Contact the prescriber explaining that the drug is a not a preferred drug
- Discuss the preferred drug options with the prescriber

#### If the prescriber agrees to switch to a preferred drug:

The pharmacist will:

#### For Original Prescriptions

- Draw a line through the original drug name, strength and directions
- Write the new drug name, strength, directions and number of refills
- Initial and note that the prescriber changed to a preferred drug

#### For Refills

- Pharmacist will note on the original prescription order that a switch has been made to a preferred drug and will create a new prescription number
- Pharmacist will not be required to obtain a new written prescription from the prescriber if a preferred drug is switched from the referenced original non-preferred prescription
- The prescription will be treated as a new prescription with the complement of refills as indicated by the prescriber

#### If the prescriber does not agree to switch to a preferred drug:

The pharmacist will explain to the prescriber that:

- He/she must contact the preauthorization center at First Health Services Corporation via telephone at 1-800-932-3918 or via facsimile at 1-800-932-3921
- The prescription cannot be filled until the preauthorization is completed

After prior authorization has been obtained by the prescriber,

**December 12, 2003** 

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred.

- The First Health Service Call Center will contact the pharmacy confirming pre-authorization
- The pharmacist can then complete the prescription, which was previously denied

When the prescriber cannot be contacted, the pharmacist is to call the preauthorization call center at 1-800-932-3918 to obtain approval for a 72-hour emergency supply of a non-preferred drug

- The pharmacist is to dispense the non-preferred drug
- Within the 72-hour window, the prescriber is to be contacted
- The pharmacist will receive a \$3.69 dispensing fee for the 72-hour supply and the recipient will not be charged a co-pay (e.g. \$0 co-pay)

When the prescriber is contacted after the 72-hour supply has been dispensed and the prescriber continues with the non-preferred drug:

- The prescriber is to be advised that he/she must obtain prior authorization before the remainder of the prescription can be dispensed
- After prior authorization has been established, the pharmacist can dispense the remainder of the prescription and receive an additional \$3.69 dispensing fee
- The appropriate co-pay will be charged to the recipient

When the prescriber is contacted after the 72-hour supply has been dispensed and the prescriber elects to switch to a preferred drug:

- Pharmacist completes the notation process previously described
- The pharmacist will receive a dispensing fee of \$4.69 and no-co-pay will be assessed to the recipient

When the pharmacist is having difficulty contacting the prescriber after the 72-hour supply has been dispensed, if necessary, a second 72-hour supply may be dispensed. However, the pharmacy <u>must</u> contact the Department for further instructions at 410-767-1455.